{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:35:46Z","timestamp":1786649746339,"version":"build-2736575974"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.4103\/sjg.sjg_169_25","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T15:00:18Z","timestamp":1762959618000},"page":"49-59","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Patterns and predictors of biologic therapy switching in inflammatory bowel disease at a tertiary care center: A retrospective observational study"],"prefix":"10.4103","volume":"32","author":[{"given":"Ahmed G.","family":"Alghamdi","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Riyadh, Saudi Arabia"},{"name":"Department of Internal Medicine, College of Medicine, Dar Al Uloom University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadeel S.","family":"Aldofaian","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed S.","family":"Alahmari","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashaar K.","family":"Alibrahim","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mishal A.","family":"Alshowair","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussam A.","family":"Alhamidi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah H.","family":"Bawazir","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, King Fahad Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal M.","family":"Aseri","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, King Fahad Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa A.","family":"Aldeibani","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, King Fahad Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohanned M.","family":"AlRaddadi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, King Fahad Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem O.","family":"Almutairi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, King Fahad Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sultan S.","family":"Alshahrani","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, King Fahad Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah D.","family":"Alenezi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, AD Diriyah Hospital, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakan H.","family":"Alshala","sequence":"additional","affiliation":[{"name":"Department of Gastroentrology, Ad Diriyah Hospital, Riyadh, Third Health Cluster, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeer M.","family":"Alhuraibi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renad M.","family":"Alharbi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"R1-20260108","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 1: Diagnosis and medical management","volume":"11","author":"Gomoll\u00f3n","year":"2017","journal-title":"J Crohns Colitis"},{"key":"R2-20260108","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3389\/fmed.2020.00517","article-title":"Personalizing treatment in IBD: Hype or reality in 2020?Can we predict response to anti-TNF?","volume":"7","author":"Atreya","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"R3-20260108","doi-asserted-by":"crossref","first-page":"10223","DOI":"10.1038\/srep10223","article-title":"Magnetic resonance enterographic predictors of one-year outcome in ileal and ileocolonic Crohn's disease treated with anti-tumor necrosis factor antibodies","volume":"5","author":"Eder","year":"2015","journal-title":"Sci Rep"},{"key":"R4-20260108","first-page":"524","article-title":"A simple index to predict the efficiency of adalimumab treatment in Crohn's disease with a limited duration of therapy","volume":"130","author":"Socha\u0142","year":"2020","journal-title":"Pol Arch Intern Med"},{"key":"R5-20260108","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/apt.12749","article-title":"Systematic review with network meta-analysis: The efficacy of anti-TNF agents for the treatment of Crohn's disease","volume":"39","author":"Stidham","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"R6-20260108","first-page":"33","article-title":"Efficiency and safety of one-year anti-TNF-\u03b1 treatment in Crohn's disease: A Polish single-centre experience","volume":"9","author":"Socha\u0142","year":"2014","journal-title":"Prz Gastroenterol"},{"key":"R7-20260108","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/apt.13083","article-title":"Systematic review with meta-analysis: The efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed","volume":"41","author":"Gisbert","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"R8-20260108","first-page":"760","article-title":"Systematic review: The short-term and long-term efficacy of adalimumab following discontinuation of infliximab","volume":"39","author":"Ma","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"R9-20260108","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/ecco-jcc\/jjz195","article-title":"Predictors of primary response to biologic treatment in patients with inflammatory bowel disease: From basic science to clinical practice","volume":"14","author":"Gisbert","year":"2020","journal-title":"J Crohns Colitis"},{"key":"R10-20260108","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.3390\/jcm10225318","article-title":"Primary failure to an anti-TNF agent in inflammatory bowel disease: Switch or swap?","volume":"10","author":"Gisbert","year":"2021","journal-title":"J Clin Med"},{"key":"R11-20260108","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.gastrohep.2017.08.006","article-title":"Ustekinumab in the treatment of Crohn's disease","volume":"40","author":"Gisbert","year":"2017","journal-title":"Gastroenterol Hepatol"},{"key":"R12-20260108","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.gastrohep.2014.12.003","article-title":"Vedolizumab in the treatment of Crohn's disease","volume":"38","author":"Gisbert","year":"2015","journal-title":"Gastroenterol Hepatol"},{"key":"R13-20260108","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.gastrohep.2019.03.002","article-title":"Efficacy of tofacitinib in the treatment of ulcerative colitis","volume":"42","author":"Pan\u00e9s","year":"2019","journal-title":"Gastroenterol Hepatol"},{"key":"R14-20260108","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/apt.14550","article-title":"Review article: Predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease","volume":"47","author":"Barr\u00e9","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"(Suppl 129)","key":"R15-20260108","doi-asserted-by":"crossref","first-page":"129","DOI":"10.55563\/clinexprheumatol\/1xi8ag","article-title":"Failure of first anti-TNF agent in Takayasu's arteritis: To switch or to swap?","volume":"39","author":"Campochiaro","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"R16-20260108","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.3390\/jcm11144157","article-title":"Predictors of anti-TNF failure in inflammatory bowel disease: A Saudi tertiary center experience","volume":"11","author":"Alharbi","year":"2022","journal-title":"J Clin Med"},{"key":"R17-20260108","first-page":"907","article-title":"Effectiveness of biologic therapies in Middle Eastern patients with inflammatory bowel disease (ENROLL study)","volume":"30","author":"Al Sulais","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"R18-20260108","first-page":"71","article-title":"A retrospective observational study of patterns of biologic drug change in inflammatory bowel disease","volume":"9","author":"Mosli","year":"2024","journal-title":"Inflamm Intest Dis"},{"issue":"(Suppl 1)","key":"R19-20260108","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.4103\/sja.SJA_543_18","article-title":"The STROBE guidelines","volume":"13","author":"Cuschieri","year":"2019","journal-title":"Saudi J Anaesth"},{"key":"R20-20260108","first-page":"1085","article-title":"Persistence with biologic therapy and associated costs of patients with inflammatory bowel disease: A German retrospective claims data analysis","volume":"21","author":"Mahlich","year":"2021","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"R21-20260108","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4097\/kja.d.18.00067","article-title":"Survival analysis: Part I\u2014analysis of time-to-event","volume":"71","author":"In","year":"2018","journal-title":"Korean J Anesthesiol"},{"key":"R22-20260108","first-page":"249","article-title":"Choosing statistical tests for survival analysis","volume":"7","author":"Ilker","year":"2018","journal-title":"Biom Biostat Int J"},{"key":"R23-20260108","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","article-title":"AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease","volume":"160","author":"Feuerstein","year":"2021","journal-title":"Gastroenterology"},{"key":"R24-20260108","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"key":"R25-20260108","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: Current management","volume":"11","author":"Harbord","year":"2017","journal-title":"J Crohns Colitis"},{"key":"R26-20260108","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders","volume":"11","author":"Magro","year":"2017","journal-title":"J Crohns Colitis"},{"key":"R27-20260108","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1053\/j.gastro.2013.10.047","article-title":"American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-\u03b1 biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease","volume":"145","author":"Terdiman","year":"2013","journal-title":"Gastroenterology"},{"key":"R28-20260108","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn's disease: Medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohns Colitis"},{"key":"R29-20260108","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.dld.2020.07.031","article-title":"The outcome of Crohn's disease patients refractory to anti-TNF and either vedolizumab or ustekinumab","volume":"52","author":"Kassouri","year":"2020","journal-title":"Dig Liver Dis"},{"key":"R30-20260108","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/1756283X09357579","article-title":"Optimal use of biologics in the management of Crohn's disease","volume":"3","author":"Panaccione","year":"2010","journal-title":"Ther Adv Gastroenterol"},{"key":"R31-20260108","doi-asserted-by":"crossref","first-page":"1756284819853208","DOI":"10.1177\/1756284819853208","article-title":"New biologics and small molecules in inflammatory bowel disease: An update","volume":"12","author":"Alghamdi","year":"2019","journal-title":"Ther Adv Gastroenterol"},{"key":"R32-20260108","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1053\/j.gastro.2015.04.016","article-title":"Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis","volume":"149","author":"Brandse","year":"2015","journal-title":"Gastroenterology"},{"key":"R33-20260108","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00228-009-0718-4","article-title":"Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis","volume":"65","author":"Fasanmade","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"R34-20260108","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/ecco-jcc\/jjz162","article-title":"Therapeutic drug monitoring of biologics during induction to prevent primary non-response","volume":"14","author":"Sparrow","year":"2020","journal-title":"J Crohns Colitis"},{"key":"R35-20260108","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10620-020-06177-7","article-title":"Hypoalbuminemia and bandemia predict failure of infliximab rescue therapy in acute severe ulcerative colitis","volume":"66","author":"Syal","year":"2021","journal-title":"Dig Dis Sci"},{"key":"R36-20260108","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Review article: Loss of response to anti-TNF treatments in Crohn's disease","volume":"33","author":"Ben-Horin","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R37-20260108","first-page":"760","article-title":"Loss of response and requirement of infliximab dose intensification in Crohn's disease: A review","volume":"104","author":"Gisbert","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"R38-20260108","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: A prospective, multicentre, cohort study","volume":"4","author":"Kennedy","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"(Suppl 3)","key":"R39-20260108","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"R40-20260108","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1038\/ctg.2015.63","article-title":"Loss of response to anti-TNFs: Definition, epidemiology, and management","volume":"7","author":"Roda","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"key":"R41-20260108","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-2036.2009.04130.x","article-title":"The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies","volume":"31","author":"Allez","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"R42-20260108","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1365-2036.2012.05214.x","article-title":"Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease","volume":"36","author":"De Silva","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"R43-20260108","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000481400","article-title":"The efficacy and safety of golimumab as third- or fourth-line anti-TNF therapy in patients with refractory Crohn's disease: A case series","volume":"2","author":"Russi","year":"2017","journal-title":"Inflamm Intest Dis"},{"key":"R44-20260108","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/ecco-jcc\/jjy004","article-title":"Primary non-response to tumor necrosis factor antagonists is associated with inferior response to second-line biologics in patients with inflammatory bowel diseases: A systematic review and meta-analysis","volume":"12","author":"Singh","year":"2018","journal-title":"J Crohns Colitis"},{"key":"R45-20260108","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2217\/cer-2017-0022","article-title":"Efficacy and safety of ustekinumab in the induction therapy of TNF-\u03b1-refractory Crohn's disease patients: A systematic review and meta-analysis","volume":"6","author":"Kawalec","year":"2017","journal-title":"J Comp Eff Res"},{"key":"R46-20260108","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/MIB.0000000000000979","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease in patients naive to or who have failed tumor necrosis factor antagonist therapy","volume":"23","author":"Sands","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"R47-20260108","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10620-022-07472-1","article-title":"Comparative long-term drug survival of vedolizumab, adalimumab, and infliximab in biologic-naive patients with ulcerative colitis","volume":"68","author":"Dalal","year":"2023","journal-title":"Dig Dis Sci"},{"key":"R48-20260108","doi-asserted-by":"crossref","first-page":"e14883","DOI":"10.1111\/dth.14883","article-title":"Ustekinumab for the treatment of paradoxical skin reactions and cutaneous manifestations of inflammatory bowel diseases","volume":"34","author":"Wu","year":"2021","journal-title":"Dermatol Ther"},{"key":"R49-20260108","first-page":"949226","article-title":"Management of non-response and loss of response to anti-tumor necrosis factor therapy in inflammatory bowel disease","volume":"9","author":"Marsal","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R50-20260108","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","article-title":"First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: An updated network meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R51-20260108","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jama.2023.15389","article-title":"Ulcerative colitis in adults: A review","volume":"330","author":"Gros","year":"2023","journal-title":"JAMA"}],"container-title":["Saudi Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_169_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:57:55Z","timestamp":1786647475000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_169_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/sjg.sjg_169_25","relation":{},"ISSN":["1319-3767","1998-4049"],"issn-type":[{"value":"1319-3767","type":"print"},{"value":"1998-4049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"2025-05-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}